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Differentiated thyroid cancer (DTC) is the most common endocrinological malignancy. There are several histological variants such as
apillary and follicular thyroid carcinoma. Many patients with well-differentiated subtypes of DTC are cured by surgery alone or with
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adioiodine, while poorly differentiated types usually have a worse prognosis. The aggressiveness of thyroid tumors is closely linked to specific
ene alterations.
Several diagnostic and prognostic molecular markers such as BRAF and RAS point mutations; RET/PTC and PAX8/PPAR gene rear-
angements; MAPK, PI3K, p53, Wnt–beta catenin, HIF1 and NF-kappaB signaling pathways; microRNA profiles and aberrant methylation
ave been demonstrated in more than 70% of DTC. Diagnostic use of these molecular markers may be optimized for identifying higher risks
f mortality, tumor recurrence and metastatic potential. Understanding the molecular biology of thyroid cancers can be an important avenue
or diagnosis and treatment of radioiodine-refractory or inoperable DTC patients with novel molecular targeted therapeutic agents.
 2014 Elsevier Ireland Ltd. All rights reserved.
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.  Introduction
Thyroid cancer is the most common malign endocrine
eoplasm originating from follicular or parafollicular thy-
oid cells. Histopathological classification of thyroid tumors
s critical for patient management and for determining the
linical course of the disease. Follicular thyroid cells derived
rom histological subtypes are follicular thyroid carcinoma
FTC), papillary thyroid carcinoma (PTC), poorly differen-
iated thyroid carcinoma and anaplastic thyroid carcinoma
ATC). FTC and PTC are classified as differentiated thyroid
arcinoma (DTC). Poorly differentiated and ATC also orig-
nate from follicular cells, and many cases are believed to
evelop as a result of dedifferentiation of a well-differentiated
apillary or follicular carcinoma. Medullary thyroid cancer
MTC) is derived from parafollicular or C cells which are
ncluded in the neuroendocrine tumor family; MTC may be a
art of multiple endocrinological malignancy type II (MEN
I) [1–3].
In the United States, approximately 23,500 new DTC
ases are diagnosed each year and its incidence has contin-
ously increased in the last three decades all over the world
xcept for a few countries (such as Norway and Sweden).
ecent reports indicated that there were 3- to 5-fold increases
n incidence rates from 1980 to 1997 depending on age,
ender, histological type of thyroid cancer, radiation expo-
ure, geographical region and other factors. The highest
ncrease in incidence was found in PTC [4]. Frequent use
f sensitive diagnostic techniques such as high-resolution
ltrasonography, computerized tomography, magnetic reso-
ance or positron emission tomography may be responsible
or incidental detection of thyroid tumors. Additionally, true
ncreases in incidence rates of thyroid cancers can also be
xplained with increased environmental radiation and use
f medical radiation, iodine intake, the Chernobyl disas-
er, carcinogens, environmental, ethnic and genetic factors
r combinations of these factors [4–7].
The most frequent type of thyroid cancer is PTC consti-
uting 75–85% of all cases. Multifocality, lymphatic or local
preading and lymph node metastases are characteristic fea-
ures of PTC whereas distant metastases by hematogenous
preading are relatively uncommon. The overall 5 and 10-
ear survival rates of PTC are approximately 97% and 93%,
espectively [6,8,9]. In most low risk patients with small
umors, no local or distant metastases and extrathyroidal
e
c
dF; RET/PTC; PAX8/PPAR
nfiltration, surgery and post-surgical radioiodine ablation
herapy is usually adequate. Moreover, for PTC patients with
1 cm tumor size, surgical treatment alone may be sufficient.
etastatic doses and repeated radioiodine therapy have been
sed for patients with lymph node or distant metastases and
xtrathyroidal soft tissue spreading [10–13]. PTCs are the
redominant histological type in children with thyroid cancer
nd in patients with head-and-neck irradiation history. The
linical course of these patients is relatively worse because
f the aggressive behavior of these tumor [3,6,8]. PTCs fre-
uently have genetic alterations such as point mutations of
RAF and RAS genes and RET/PTC rearrangements. These
enetic alterations are found in more than 70% of the patients
nd may have prognostic implications [14–17].
FTC is second most common thyroid malignancy and
ccounts for 10–15% of thyroid cancers [6,8]. FTC tends to
etastasize to lung and bone via  the bloodstream. Prognosis
f FTC is worse than PTC especially in patients with distant
etastases. The overall 5 and 10-year survival rates for follic-
lar thyroid cancer are 91% and 85%, respectively. Treatment
trategy is thyroidectomy followed by ablative or metastatic
oses of radioiodine therapy [12,13,18,19]. Approximately
0% of FTC patients have mutations in RAS family genes or
AX-PPAR rearrangements [14,20,21].
ATC is an uncommon, lethal malignancy of older adults.
he mean survival time is usually less than 6 months from the
ime of diagnosis and this outcome is not altered by current
reatments. Patency of the airway is critical for the patient’s
ourse due to aggressive local spreading of the primary tumor
nd airway obstruction is the primary cause of death in most
atients [1].
Thyroid follicular cells trap iodine by a Na+/I− Sym-
orter (NIS), which is an energy-dependent transport system
egulated by thyroid stimulating hormone (TSH). Iodine is
rganified by thyroid peroxidase (TPO) at the apical surface
f the thyroid cells and then conjugated to thyroglobulin (Tg).
odine is also trapped and organified by DTC cells as in thyro-
ytes and this unique characteristic plays the most important
ole on treatment and diagnosis of DTC [22–24]. 131 Iodine
131I) is a  and   emitting radionuclide and chemically iden-
ical to the non-radioactive form of iodine. Radioiodine is an
ffective therapeutic and imaging agent for DTCs. Dediffer-
ntiated, poorly differentiated and anaplastic thyroid tumor
ell clones have lost the ability to trap iodine. Thus, radioio-
ine is not effective for detection and therapy of these tumors
n Onco
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25]. Non-radioiodine avid tumors have aggressive behavior
nd poor prognosis.
Whereas radioiodine is the primary therapeutic agent for
TC, clinical response of residual or recurrent tumor and
istant metastasis is variable. Age, gender, tumor histologi-
al type, clinicopathological features, stage of the disease,
resence of distant metastasis, ability to trap radioiodine
nd molecular genetic alterations may be responsible for the
ggressive clinical course of the disease. Molecular profil-
ng of he thyroid cancers is important for determination of
rognosis, causes of treatment resistance and targeted therapy
ptions especially in radioiodine refractory patients.
In recent years, knowledge about genetic aberrations in
hyroid cancers has significantly increased. Accumulating
ata on the molecular biology of thyroid cancers can be an
mportant avenue for diagnosis, classification and treatment
f thyroid cancers. In this comprehensive review article, we
pdate the data generated on molecular biology of thyroid
ancers and discuss the translational aspects of thyroid cancer
olecular biology.
.  Genetic  changes  in  thyroid  cancer
PTC and FTC are the most common types among all thy-
oid malignancies and the development of molecular markers
or these tumors is very significant in terms of diagnosis,
rognosis, treatment and follow up [26–28]. Four different
ene mutations with significant effects on tumor prognosis
nd diagnosis have been identified. They are BRAF and RAS
oint mutations, and RET/PTC and PAX8/PPARc rearrange-
ents.
.1.  BRAF
BRAF, a member of the RAF protein family, is a
erine–threonine kinase. As RAS binds and activates BRAF,
t is translocated to the cell membrane and directly associates
ith the MAPK signaling pathway [14]. BRAF phospho-
ylates and activates MEK, which in turn activates ERK
nd all the downstream effector molecules of MAPK. Acti-
ated ERK and ELK1 translocate to the nucleus and regulate
ranscription of genes involved in cell differentiation, pro-
iferation, and survival (Fig. 1) [26,14]. The most common
enetic changes in PTC include point mutations of BRAF
hich are observed in 35–70% of papillary thyroid carcino-
as [29,30]. More than 95% of BRAF mutations detected in
hyroid cancers are thymine to adenine transversions at posi-
ion 1799 (T1799A) resulting in the substitution of valine by
lutamate at residue 600 (V600E) (Table 1) [31]. This muta-
ion causes constitutive activation of BRAF kinase and, thus,
nduction of the MAPK signaling pathway, which is respon-
ible for thyroid tumorigenesis [14,31]. In small percentages
f PTC, K601E point mutation, small deletions or inser-
ion around codon 600 and AKAP9/BRAF rearrangement are
lso be observed [30]. There is a direct association between
w
e
t
ology/Hematology 90 (2014) 233–252 235
RAF mutation and aggressive clinical outcomes such as
nvasion, metastasis and relapse of PTC [32]. It has also
een demonstrated that BRAF mutation is associated with
oss of radioiodine avidity in recurrent PTC which cannot
e cured [33]. Several studies demonstrated a close asso-
iation between BRAF mutation and dedifferentiation of
TC [32–34]. All the rearrangements and mutations increase
RAF activity and cause continuous induction of the MAPK
ignaling pathway.
Effects of BRAF mutations on induction and dedifferenti-
tion, in addition to its effects on tumor aggressiveness, were
xamined in a transgenic mice model with V600E BRAF. The
esults revealed that these transgenic animals had PTCs and
howed invasion, a common property of aggressive tumors
35]. All these data suggest that mutations in BRAF can be
sed as a novel marker for the prognosis of thyroid cancer.
.2.  RET/PTC  rearrangements
RET (rearranged during transfection), a proto-oncogene,
ncodes for a membrane-bound receptor tyrosine kinase and
s highly expressed in calcitonin-producing parafollicular
ells (C cells) in the thyroid gland (Table 1) [36]. The acti-
ation of the RET gene in follicular cells as a result of a
hromosomal rearrangement called RET/PTC plays impor-
ant roles especially in the pathogenesis of childhood PTCs
nd PTC arising from radiation exposure [36,37]. RET/PTC
earrangements are characterized by a fusion between the
yrosine kinase domain of the RET gene located on the 3′ and
′ terminii of various partner genes [38]. Based on the partner
enes, at least 10 different types of RET/PTC rearrangements
ave been identified. Of these, the most common types in PTC
re RET/PTC1 and RET/PTC3 [39,40]. The partner genes
or RET/PTC1 and RET/PTC3 are the coiled-coil domain
ontaining gene 6, CCDC6 (also called H4/D10S170) and
he nuclear receptor co-activator gene 4, NcoA4 (also called
FG/ELE1) genes, respectively [36,41]. Oncogenic activity
f RET/PTC is related with the MAPK signaling cascade. In
his cascade, RET/PTC first binds to adaptor proteins such as
RB2 and SOS and then activates RAS. Then, RAS activates
AF kinases such as BRAF and the downstream signaling
ascade including MEK and ERK [42]. Although the exact
ole of RET/PTC at the early stage of thyroid tumorigenesis
s unknown, a correlation between the presence of RET/PTC
nd a high growth rate of benign thyroid tumors has been
ound in a recent study [43]. Therefore, testing for RET/PTC
earrangements by different molecular approaches will be
elpful for the diagnosis of thyroid cancer [44].
.3.  The  MAPK  signaling  pathway
The mitogen-activated protein kinase (MAPK) path-
ay plays a major role in terms of regulating cellular
vents, such as proliferation, survival, and is also known
o affect tumorigenesis. Genetic and epigenetic alteration
f the RAS–RAF–MEK–MAPK–ERK pathway is the most
236 O. Omur, Y. Baran / Critical Reviews in Oncology/Hematology 90 (2014) 233–252
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ommon, and was shown to highly affect thyroid cancer,
articularly for PTC (Fig. 1) [45,34].
As mentioned earlier, the MAPK signaling pathway
egulates cell proliferation, differentiation and survival by
llowing the cells to respond to external stimuli by inter-
ction of cellular tyrosine kinases (such as RET and
-protein-coupled receptors) with hormones, growth factors
nd cytokines [46]. The MAPK pathway also has a major
ole in human tumorigenesis. In thyroid cancer, RET/PTC
earrangements and point mutations in RAS and BRAF
enes have been shown to activate the MAPK pathway
47–51]. Following the activation of the MAPK pathway, sec-
ndary molecular events occur, such as hypomethylation and
enome-wide hypermethylation, which augment the tumori-
enic activity of this pathway [52]. In addition, upregulation
f several oncogenic proteins, such as chemokines [53,54],
uclear factor B (NF-B) [55], vascular endothelial growth
actor A (VEGFA) [56], matrix metalloproteinases (MMPs)
53,55,57], MET [58,59], vimentin [60], prokineticin 1
PROK1; also known as EG VEGF) [61], prohibitin [62],
ypoxia-inducible factor 1  (HIF1) [63], thrombospondin
 (TSP1) [64], urokinase plasminogen activator (uPA) and
s
p
o
vys in thyroid cancers.
ts receptor (uPAR) [65,66] and transforming growth factor
1 (TGF1) [67,68] drive cancer cell growth, proliferation
nd survival, together with tumor angiogenesis, invasion and
etastasis.
.4.  The  PI3K/AKT  signaling  pathway
The phosphatidylinositol 3-kinase (PI3K)/Akt signaling
athway has major roles in several cellular events includ-
ng growth, proliferation and apoptosis [69,70]. Activation
f this pathway leads to tumorigenesis including thyroid
arcinoma [71,72]. The role of the PI3K/AKT pathway on
hyroid tumorigenesis was first revealed by the finding that
owden’s syndrome (which is caused by germline mutations
f PTEN) was associated with follicular thyroid adenoma
FTA) and FTC [73]. Activation and increased expression
f Akt has been shown to activate the PI3K/Akt pathway
nd lead to thyroid tumorigenesis (Fig. 1). FTCs have been
hown to have higher levels of Akt activation as compared to
apillary carcinoma and normal tissues [74,75]. Three types
f Akt have been identified: Akt-1, Akt-2 and Akt-3. Acti-
ated Akt induces the signaling cascade by phosphorylating
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Table 1
Thyroid tumors with their characteristics and mutational profiles.
Tumor type Prevalence (% of
thyroid cancers)
10-Year survival (%) Mutations observed and their
prevalence
Effects of these mutations on tumor
Papillary carcinoma 80–85 95–98%
BRAF (V600E) 45%
Promoting tumorigenesis, invasion,
metastasis, recurrence and mortality
RET/PTC 20%
RAS 10%
TRK <5%
Follicular carcinoma 10–15 90–95
RAS 45%
Promoting tumorigenesis, invasion,
metastasis, recurrence and mortality
PAX8-PPARy 35%
PIK3CA <10%
PTEN <10%
BRAF (V600E) <10%
Medullary carcinoma 3–5 60–80
Familial forms of RET >95%
Sporadic RET 50%
Poorly differentiated
carcinoma <2 50
RAS35%
Promoting tumorigenesis and tumor
progression, invasion, metastasis,
recurrence and mortality
BETA CATENIN 20%
TP53 20%
BRAF 15%
PIK3CA 10%
AKT 10%
Anaplastic carcinoma 1–2 <10
TP53 70%
Promoting tumorigenesis and tumor
progression, invasion, metastasis,
recurrence and mortality
BETA CATENIN 65%
RAS 55%
BRAF 20%
PIK3CA 20%
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ay, cell proliferation is promoted and apoptosis is inhibited.
kt-1 and Akt-2 were shown to be the most important genes
n thyroid cancer [76]. It was previously determined that
utations, or amplification and genomic copy gain of the
I3KCA gene, encoding the catalytic subunit of PI3K, occur
n thyroid tumors [77–79]. Decreased expression or inac-
ivation of the tumor suppressor gene product PTEN and
ctivation by RAS oncogenes have also been described to
ctivate the PI3K/Akt signaling pathway and play a role
n thyroid tumorigenesis [78–80]. Combinations of some of
hese PI3K/Akt genetic alterations, as well as combinations
f these alterations with BRAF mutation, were shown to be
resent in more aggressive thyroid tumors such as ATC [78].
enetic alterations that activate both MAPK and PI3K/Akt
athways were shown to be present in most (81%) ATC cases.
In a transgenic mouse model where a mutant thyroid
ormone receptor   gene (TRPV) was knocked-in, the
I3K/Akt pathway was shown to be activated following inter-
ction of TRPV with the p85  regulatory subunit of PI3K,
nd spontaneous development of FTCs was observed [81,82].
everal human tumor studies proposed that activation and
uclear localization of Akt1 is involved in the invasiveness
nd metastasis of FTC induced by the PI3K/Akt pathway
83]. This proposal-was supported by the detection of Akt1
utations in metastatic thyroid cancers [84]. On the other
and, excision of Akt1 was shown to delay and prevent tumor
evelopment, angiogenesis, and movement of FTC to distant
ites in TRPV mice [85].
F
[
a
lPTEN <10
AKT 10%
.5.  RAS
The family of RAS (an abbreviation of RAt sarcoma)
ncogenes encodes 21 kDa-G-proteins that transmit signals
rom the receptors on cell membrane to several types of
argets in the cell controlling MAPK and PI3K signaling
athways in thyroid cancer [86,87]. There are three different
AS genes, known as HRAS, KRAS, and NRAS, that pass
he signals from cell membrane receptors to their intracel-
ular adaptor molecules (Fig. 1) [86,87]. RAS proteins exist
s an active form with guanosine triphosphatase (GTPase)
ctivity and an inactive form that is bound to guanosine
iphosphate (GDP). Generally, point mutations in codons
2, 13, and 61 of the RAS oncogene are observed in thyroid
ancer. While the point mutations in codons 12 and 13
esult in elevated affinity for GTP, point mutation in codon
1 leads to repression of GTPase activity in autocatalysis
86–88]. All of these point mutations fix the RAS protein in
ctivated states and, therefore, result in continuous stimu-
ation of downstream targets of RAS. This, in turn, results
n instability of the genome, induction of other mutations,
nd transformation into malignancy (Table 1) [89]. These
utations are seen at different frequencies in different
ypes of thyroid cancers. While in PTC, RAS mutations
ere observed in approximately 10% of cases, in ATC and
TC this frequency is 10–20% and 40–50%, respectively
90–93]. RAS mutation in PTC leads follicular variants,
nd also more encapsulation, and fewer metastases to
ymph node [94,95]. In ATCs, RAS mutations are generally
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bserved in tumors that develop microfollicular pattern
96].
Studies on RAS mutation in different types of thyroid can-
er have shown that these mutations are observed in both
alignant and benign types of tumors [97]. However, codon
1 point mutations have been especially reported to cause
umor progression in an aggressive manner [98,99]. Stud-
es with transgenic mice demonstrated that RAS mutations
esulted in carcinogenesis and hyperplasia in thyroid [100].
.6.  PAX8/PPARγ rearrangement
The PAX8 gene encodes a transcription factor required for
he generation of thyroid follicular cells and tissue-specific
ene expression in thyroid. The peroxisome proliferator-
ctivated receptor   (PPAR) gene is a member of the
uclear hormone receptor superfamily including retinoic
cid, estrogen receptor, androgen receptor, and also thyroid
ormone [101]. The PAX8/PPAR rearrangement occurs
s a result of genetic translocation between chromosomes
 (exon 7, 8 or 9) and 3 (exon 1), t(2;3)(q13;p25) [102].
lthough the main mechanism is not yet clear, this fusion
esults in significant increases in expression of PAX8/PPAR
himeric protein which inhibits the tumor suppressor activ-
ty of PPAR  [103–106]. Deregulation of PAX8 function,
ssential for differentiation of thyroid cells, and induction
f some other genes, that are unrelated to wild type PAX8
r PPAR  genes, may be responsible for generation of thy-
oid cancer after this rearrangement [107,108]. Generally,
AX8/PPAR rearrangement is seen in follicular thyroid
arcinoma at 30–35% frequency (Table 1) [109,110]. In
ddition, most studies have shown that this rearrangement
s also seen in follicular adenomas at 2–13% frequency,
nd in papillary carcinomas with follicular variants at 1–5%
requency [111–113]. Rarely, in 1 out of 42 follicular carci-
omas, another type of gene rearrangement of PPAR  with
REB3L2 (CREB3L2/PPAR ) was observed [114].
.7.  p53
The p53 gene encodes a transcription factor that regu-
ates vitally important cellular functions such as cell growth,
roliferation, cell cycle, apoptosis and DNA repair [115].
xpression of p53, known as the guardian of the genome,
s triggered when the cells are under stress conditions and
ell cycle progression is inhibited. Damage to the DNA is
hen repaired or the cells undergo apoptosis [116]. However,
oint mutations that inactivate the tumor suppressor gene,
P53, are common events in the initiation of cancer. In thy-
oid tumors, loss of TP53 gene activity is observed at a later
tage. p53 loss is generally observed in 15–30% of poorly dif-
erentiated carcinomas, in 60–80% of ATCs, and is extremely
are in DTCs (Table 1) [86,117–120]. p53 inactivation in
hyroid cells has been shown to enhance tumor growth and
lso causes continuous loss of differentiation. In one study,
t was observed that the progressive loss of differentiation in
o
(
elogy/Hematology 90 (2014) 233–252
TC and poorly differentiated carcinomas is controlled by
nactivation of the p53 gene [121,122].
The first mouse model of ATC was recently generated
ased on information provided by research and patient-
erived genetic data. It is known that molecular changes that
haracterize ATC are: inactivation of the TP53 gene or acti-
ation of the PI3K cascade, RAS family members, or BRAF
123,124]. Mouse thyroid follicular cells were used in the
tudy for which inactivation of the TP53 gene was combined
ith constitutive activation of the PI3K signaling cascade, via
eletion of the PTEN tumor suppressor. The tumors develop-
ng in these mice were observed to closely resemble human
TCs, and they were shown to undergo glycolytic shift and
onsequently respond to glycolytic inhibitor therapy.
It was demonstrated that loss of p53 triggers dedifferen-
iation of thyroid tumors. PTC developed in transgenic mice
ith thyroid-specific RET/PTC rearrangements while cross-
ng with p53−/− mice, the progeny was developed [125,126].
n the other hand, expression of thyroid specific genes
as detected after introduction of wild-type p53 into ATC
127,121].
It is known that p53 mutation is rarely found in thyroid
ancer, mainly in undifferentiated tumors, and it is gener-
lly involved in the progress of advanced cancer. However,
ecently, there is evidence indicating that p53 mutation may
lso be effective in the early stages of thyroid cancer. In these
umors, various inactivating mechanisms acting on the pro-
ein and/or its signaling pathway may inhibit wild-type p53
ctivity [122]. It is assumed that p53 mutations may be an
nitiator in poorly differentiated or ATC; but it is a late event
ontributing to the development of transformed phenotype.
.8.  WNT–beta  catenin  pathway
Abnormal activation of the Wnt signaling pathway leads
o the development of epithelial tumors. In recent years, the
mportance of the Wnt/-catenin pathway in the initiation of
hyroid cancer has gained significance. This pathway plays
 major role in tumor development and epithelial renewal.
n thyroid tumors, the most frequent mutations are found in
he scaffold proteins adenomatous polyposis coli (APC) and
xin, as well as in -catenin (Fig. 1) [128].
Poorly differentiated and ATCs constitute additional
enetic changes that are normally not found in well-
ifferentiated cancers. These changes represent late events,
hich may be involved in the initiation of tumor differentia-
ion. One of these late events is the formation of mutations in
he CTNNB1 gene, which encodes -catenin, a cytoplasmic
rotein that has a role in cell adhesion and is known to be an
mportant intermediate in the wingless (Wnt) signaling path-
ay [129,130]. Point mutations occur in exon 3 of the gene
hese mutations have been found in 66% of ATCs and 25%
f poorly differentiated carcinomas, although not in DTCs
Table 1) [131,132].
The direct role of -catenin in proliferation of undiffer-
ntiated thyroid tumor cells has been understood. However
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ore studies should be undertaken to determine the role
f -catenin in the earlier stages of thyroid tumor progres-
ion. The use of in  vivo  models which have a constitutively
ctive Wnt/-catenin pathway could help to understand the
echanism by which the Wnt pathway promotes tumor
evelopment in thyroid cancer.
.9.  The  NF-κB  signaling  pathway
The NF-B pathway is one of the main players in the
egulation of inflammatory responses that are involved in
nduction of cancer [133]. There are significant increases
n activity of NF-B in thyroid cancer cells and tissues
134–136].
Inhibition of NF-B protein synthesis with specific anti-
ense oligonucleotides significantly decreased growth rate
f undifferentiated carcinoma cells [136]. This decrease
as related to suppressed expression of c-myc, a target
or NF-B118. NF-B is a transcription factor that induces
xpression levels of different oncogenes and is upregulated
y the MAPK pathway, RET/PTC, RAS and BRAF-V600E
n thyroid cancers [137]. Recently, it was shown that prolife-
ative and anti-apoptotic genes were regulated by the NF-B
ignaling pathway in thyroid cancer [137,138]. The mecha-
ism of BRAF-V600E induced increases in expression levels
f NF-B and was related with IB (inhibitor of NF-B)
egradation in thyroid cancer cells [55].
.10.  MicroRNAS
Micro-RNAs (miRNAs) are small noncoding RNA genes
omposed of 21–25 nucleotides. They inhibit expression
evels of genes at the transcriptional and posttranslational
evels [139]. The aberrant expression of certain miRNAs can
nduce initiation and/or progression of human cancers [140].
he involvement of miRNAs in proliferation, differentiation
nd apoptosis have been defined and thus they could be used
s biomarkers for diagnostic and therapeutic targets in many
ancers including lung, pancreas, breast, and colorectal
ancers in addition to thyroid cancers [141–144]. There are
everal reports displaying changes in miRNA profiles in thy-
oid cancers as compared to normal thyroid tissues [143,144].
ased on cellular origin and degree of tumor differentiation,
ifferent miRNAs are expressed in thyroid cancer [145].
articularly miR-222, miR-221, and miR-146b have been
ound to be the most upregulated miRNAs in PTC. It was
hown that miRNA-221 was also upregulated in unaffected
hyroid tissue of several PTC patients, which was considered
s an early event in carcinogenesis [146]. Moreover, the
ssociation between increased expression of miR-222, miR-
21, and miR-146b and pathological features of PTC has
een examined and revealed that expression levels of these
iRNAs were strongly related with extrathyroidal invasion.
n addition, miR-146b was found to be highly expressed
n PTC samples [147]. miR-222, miR-221, and miR-146b
ave been thought to play crucial roles in PTC initiation
w
a
t
alogy/Hematology 90 (2014) 233–252 239
nd development. The candidate targets of these miRNAs
ould be p27kip1, a cell cycle progression inhibitor, and
IT, a receptor tyrosine kinase that plays important roles in
ell growth and differentiation [143,148]. Interestingly, high
xpression levels of miR-146b were found to be correlated
ith lower overall survival and with the development of drug
esistance [149]. A recent study demonstrated that miR-146b
ould cause thyroid cancer development by regulating
GF- signaling, although the mechanisms of miR-146b-
ediated tumor behavior in PTC are largely unknown [150].
here were also significant increases in expression levels of
iR-146b, miR-221, miR-222 and miR-135b in samples of
TC patients with extrathyroidal invasion [151].
There was an association between upregulation of
iR-193b, miR-2861, miR-1202, and miR-451 and downreg-
lation of miR-let-7i, miR-542-5p, miR-664, and miR-564
ith lymph node metastasis [152]. Yu et al. identified the
irculating miRNA profiles of PTC patients and showed that
here were significant increases in serum let-7e, miR-151-5p,
nd miR-222 in PTC cases. An association with certain clin-
copathological features such as tumor size and metastasis
tage and expression levels of these miRNAs was also deter-
ined [153]. There were also significant downregulation of
xpression of certain miRNAs including miR-1, -191, -486,
nd -451 in PTC [154]. miR-1 silences CXCR4 which plays
 major role in lymph node metastasis [155]. Therefore, its
ownregulation via  miR-1 could be a potential strategy for
vercoming lymph node metastasis. Recently several stud-
es have reported the importance of miRNA deregulation in
TCs, although most of the studies have focused on PTCs.
eber et al. found four miRNAs, miR-192, -197, -328, and
346, that seem to be specific for FTCs since they have not
et been associated with other thyroid cancer types [156].
he targets of miR-197 are ACVR1 and TSPAN3 genes
hile EFEMP2 is the target of miR-346 [156]. The EFEMP2
ene is thought to have tumor suppressor functions while the
CVR1 and TSPAN3 genes are involved in the control of
ell growth and metastatic potential, respectively [157–159].
n vitro  studies related with these miRNAs showed that their
verexpression induced significant cell proliferation whereas
nhibition caused growth arrest in human thyroid carcinoma
ollicular cells [154,156].
In conclusion, miRNA expression profiles demonstrate
ifferences between thyroid tumors and healthy tissues,
rimary tumors and metastatic tumors, and even between dif-
erent regions of the same tumor. Therefore, miRNAs could
e used as a novel marker for tumor diagnostic purposes.
.11.  The  HIF1α  pathway
Hypoxia-inducible factor (HIF)-1, through binding to
IF1 (known as ARNT), forms HIF1 transcription factor
hich triggers the expression of genes regulating tumor
ngiogenesis [160]. It was demonstrated by several groups
hat HIF1  is expressed in thyroid tumors, such as ATC,
nd is not expressed in healthy thyroid tissues [161,162].
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 significant increase in expression levels of HIF1  in
HP10-3SC (mice) and human PTC tissue was determined
163]. HIF1 induces expression of VEGF, a growth factor,
nd MET, an oncogene, which are also upregulated in thyroid
umors as compared to normal thyroid tissues [162]. On the
ther hand, PI3K-AKT and MAPK increase expression of
IF1 in thyroid tumor [161,164,165] while a mutation in
RAF (V600E) also affects expression levels of HIF1  in
apillary thyroid cancer [165]. Interestingly, inhibition of
xpression levels of HIF-1  and HIF-2  by GDC-0941 in
our different thyroid tumor cells (BcPAP, WRO, FTC133,
nd 8505c) resulted in inhibition of VEGF secretion [166].
operek et al. demonstrated that tumor hypoxia is involved
n the development of regional metastases in MTC [167]. All
hese results suggest that HIF1 can be used as a diagnostic
nd even prognostic marker for thyroid tumors. More impor-
antly, targeting HIF1 with special inhibitors could be a novel
pproach for effective treatment of thyroid cancers since it
nduces angiogenesis and metastasis of thyroid tumors.
.12.  Aberrant  methylation
Changes in methylation status of the genome are hallmarks
f cancers including thyroid cancer [168]. Hypermethylation
f many tumor suppressor genes was determined for thy-
oid cancer by several groups [168]. Aberrant methylation
esults in downregulation of the genes as it occurs in regu-
atory sequences. It was determined that the BRAFV600E
utation is associated with hypermethylation of various
umor suppressor genes, such as death-associated protein
inase 1 (DAPK1), retinoic acid receptor-  (RARB), tis-
ue inhibitor of metalloproteinases 3 (TIMP3) and SLC5A8
169]. Interestingly, Hou et al. demonstrated that BRAF-
600E signaling induced changes in methylation, both
ypermethylation and hypomethylation, and methylation
egulates high numbers of genes involved in the control of
ital important cellular functions in PTC cells [170]. An
ssociation between BRAF mutations and aberrant methyla-
ion of DNA repair genes, especially the hMLH1 gene was
etected which also determines the aggressiveness of PTC
170,171]. These results revealed that changes in methyl-
tion levels resulting from BRAF-V600E are important in
nduction of thyroid cancers.
Methylation of PTEN in regulatory sequences resulting
n downregulation of expression of PTEN is also observed in
TC [172–174]. Methylation of PTEN is related with changes
n the PI3K–AKT pathway, mutations in RAS, and mutations
nd amplifications in PIK3CA in thyroid tumors [171]. It
as shown that increased activity of the PI3K–AKT pathway
nduces changes in methylation and downregulates PTEN
172].Thyroid molecules including NIS, TSH, Tg, TPO recep-
ors, and pendrin are generally lost in thyroid tumors because
f aberrant methylation. This aberrant methylation is regu-
ated by the BRAF mutation-promoted MAP kinase signaling
i
R
e
plogy/Hematology 90 (2014) 233–252
athway and inhibition of MAP kinase by specific chemicals
an reverse this event [168].
Although genetic problems were clearly identified for
any thyroid cancers, around 30–35% of DTCs could not be
xplained by genetic problems. This indicates that changes
n epigenetics should be further investigated.
.  Molecular  targets  in  histopathological  diagnosis
nd classification  of  thyroid  cancer
Histopathological examination is essential in current clin-
cal practice to classify histological subtypes or variants and
o distinguish malign thyroid tumors from benign ones. The
istopathological classification recommended by WHO has
een used for distinguishing thyroid tumor types in post-
perative thyroidectomy materials and the Bethesda system
as been used for classifying thyroid cytopathology of fine
eedle aspiration biopsy (FNAB) samples [175]. For many
hyroid tumor types such as follicular patterned tumors (fol-
icular adenoma, FTC, minimally invasive FTC and follicular
ariant of PTC) and several variants of PTC, histological
r cytological criteria are subjective. Thus it is possible
o have diagnostic errors, problems and interobserver vari-
bility. Furthermore, reliable prognostic markers are still
nsufficient. The most prominent interobserver variability has
een reported in follicular-patterned tumors [175–178]. Final
greement for reported criteria such as capsular or vascular
nvasion and differential diagnosis of follicular adenoma and
arcinoma is very low (27, 20 and 37%, respectively) [177].
ome disagreements between pathologists have also been
eported for classification of histological variants of PTC and
NAB [175–178].
Morphological and biological characteristics of FTA and
TCs are very similar and thus it may be impossible to make
efinitive differential diagnosis by FNAB sampling. There-
ore, 10–40% of all FNABs are reported as indeterminate for
alignancy. Many immunohistological markers have been
mproved for more accurate differential diagnosis of thyroid
umors. However they have limited use in routine practice
ecause many of them show overlap between some subtypes
f thyroid cancer [179].
Molecular markers hold promise to improve preoperative
iagnosis of thyroid cancer. Diagnostic use of gene mutations
BRAF, RAS, PET/PTC, PAX8/PPAR), alterations in gene
xpression profile and miRNA signatures have several advan-
ages in differential diagnosis of thyroid tumors. Identifying
pecific molecular or genetical alterations offers not only the
ossibility of distinguishing benign and malign tumors and
o classify thyroid malignancies but also to make progno-
tic stratification. Diagnostic use of mutational markers as
ingle gene analyses or a panel of mutations may help to
mprove the accuracy of FNAB. RET/PTC, BRAF, NTRK,
AS and PAX8–PPAR mutations have been frequently
xplored for diagnosis of thyroid cancer. Gene expression
rofiling and microRNA studies have identified a variety
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f potential molecular markers to help distinguish benign
rom malignant thyroid neoplasms especially for nodules
hat are classified as indeterminate for malignancy by FNAB
36,37,45,34,90–93,109–113,178,180–182]. The inability to
xclude malignancy in these nodules may often lead to unnec-
ssary surgery or two step surgical procedures. More accurate
reoperative diagnosis significantly reduces the frequency of
nnecessary surgery and thus patient morbidity.
PTCs are a histologically heterogeneous group of
umors that are classified as classical, follicular, tall-cell,
olumnar-cell, cribriform-cell, onchocytic (hurtle cell), dif-
use sclerosing and solid variants. The role of molecular
iagnostic markers on classification of PTC is uncertain.
he vast majority of PTCs are characterized by mutations
r rearrangements along the MAPK pathway like RET/PTC
earrangements and BRAF mutations.
The prevalence of RET/PTC rearrangements in PTC is
ariable (0–87%) depending on histological subtype, age,
eographical factors, radiation exposure and detection meth-
ds but such rearrangements represent most of the cases with
o or very low incidence in FTC and ATCs. Initial reports
uggested that RET/PTC was specific for PTC [183,184]
ut later it was also found in some benign lesions [185,186]
nd diseases such as Hashimato disease [187]. According to
hese results, RET/PTC is not a specific PTC marker. How-
ver, recent studies suggested that RET rearrangements in
enign thyroid nodules could be associated with a higher
rowth rate of the nodule, thus, RET/PTC positive benign
odules must be subjected to careful follow-up [188–190].
ET/PTC1 and RET/PTC3 are the most common isoforms of
ET/PTC, with the first predominant in the classical type of
TC and the second predominant in the solid variant of PTC
180,191]. RET/PTC3 is also predominant among radiation-
nduced PTCs such as post-Chernobyl PTCs and has more
ggressive behavior [192,193]. However, there was no sig-
ificant correlation found in the occurrence of RET/PTC in
atients with and without history of medical radiation [194].
resence of RET/PTC activation may be a complementary
pproach in patients reported to have indeterminate cytology
y FNAB and with borderline histological features of malig-
ancy in microscopic papillary foci of thyroid nodules [195].
ost studies demonstrated that the sensitivity of molecular
ssays has improved by combined detection of BRAF and
ET/PTC. An increased sensitivity from about 42.3–69% to
6.4–78% has been reported [196–198].
The BRAF point mutation is the most common mutation
n PTC (35–70%) and has recently been reported to be
ssociated with poor prognostic features like extrathyroidal
oft tissue infiltration, lymph node metastasis, disease
ggressiveness, tumor recurrence, loss of radioiodine
vidity and, thus, resistance to annual therapeutic methods
29–34,199,200]. Additionally, the BRAF mutation occurs
ost commonly in aggressive subtypes of PTC [178,201].
oss of NIS and TPO are early markers of dedifferentiation
nd they are also responsible for poor prognosis in BRAF
ositive PTCs [202]. According to these results, the BRAF
p
B
g
plogy/Hematology 90 (2014) 233–252 241
utation is a potential independent prognostic molecular
arker for PTC. More extensive surgery, higher doses of
adioiodine, lower levels of suppression of TSH and closer
onitoring during the follow-up period will be helpful for
isease control in patients with BRAF positive PTC.
Because of its high prevalence and specificity to PTC and
TC-derived dedifferentiated tumors, screening the BRAF
utations in FNAB samples may be useful for preopera-
ive diagnosis [203,204]. Recent studies reported that the
RAF mutation is a highly accurate marker of malignancy
or thyroid nodules sampled by FNAB [205–209]. However,
he most frequent diagnostic problems in FNAB samples are
ndeterminate follicular tumors and suspicion of malignancy
ccording to the Bethesda system. The diagnostic potential
f the BRAF mutation is relatively low for indeterminate
ollicular neoplasms [210]. Additionally, BRAF mutations
emonstrate a high geographical variability and local fre-
uency must be taken into consideration for evaluation of
he results. Despite these factors, recent studies reported that
80 of 581 BRAF-positive nodules were PTC and the false
ositive rate of BRAF mutational analysis was only 0.2%
26,28]. Moreover 15–40% of BRAF-positive FNAB sam-
les were indeterminate by cytology. These reports indicate
hat BRAF analysis on FNAB samples is a reliable diagnostic
arker for PTC. Despite high specificity, analyses of BRAF
lone in FNAB samples may miss some thyroid cancers that
re negative for BRAF mutation.
In FTC, RAS mutations and a fusion oncogene between
AX8 and PPAR  have been more frequently observed than
ollicular adenoma. Frequency of RAS mutation, the sec-
nd most common mutation after BRAF, is about 40–50%
n FTCs and 10% in PTCs (follicular variants) [90–93]. The
ositive predictive value of RAS mutation positivity in FNAB
amples for thyroid cancer is about 74–87%. Detection of the
AS mutation is associated with an 87–100% probability
f malignancy [28]. Most importantly, RAS-positive thyroid
ancers are FTC and the follicular variant of PTC which may
ause false negative results in cytological evaluations. These
esults suggest that the diagnostic value of RAS mutation in
NAB samples is high for DTCs. Total thyroidectomy has
een suggested as the initial surgical procedure in patients
ith thyroid nodules that are positive for the RAS mutation
y FNAB due to the high preoperative probability of cancer
32]. PAX8/PPAR rearrangement is characteristically seen
n FTCs and it may be used as a diagnostic marker. However,
AX8/PPAR mutation is rarely observed in some follicular
denomas. Detection of the PAX8/PPAR mutation should
lert the pathologist to re-examination for histological fea-
ures of follicular carcinoma such as vascular or capsular
nvasion [26,28].
Several studies reported that the most effective diagnostic
tility can be achieved by a panel of mutations in FNAB sam-
les. Ohori et al. suggested a panel of biomarkers including
RAF-RAS gene mutations and RET/PTC-PAX8–PPAR
ene translocations to optimize FNAB results [211]. This
anel includes some of the most frequent and specific
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olecular markers identified to date for thyroid cancer
nd may be used in routine practice. TRK rearrangements
ay also be added to this panel. Presence of BRAF, RAS,
ET/PTC, PAX8–PPAR and TRK in FNAB samples
orrelated with malignancy in 97% of cases [196,197,212].
herefore, detection of any mutation of this panel is a strong
redictor for thyroid cancer. The revised American Thyroid
ssociation’s (ATA) Management Guideline recommended
sing a mutational panel for nodules classified as indetermi-
ate by FNAB [213]. Nodules with indeterminate cytology
ave a 5–10% probability for malignancy and usually
ndergo repeated FNAB according to classical follow-up
rotocols [175,214]. Analysis of a panel of mutations
s particularly useful for management of patients with
ndeterminate thyroid nodule that are at the low risk category
or thyroid cancer. The most common mutations in these
odules are RAS, BRAF and PAX8–PPAR rearrangement.
etection of these molecular alterations indicates a high risk
ategory for malignancy. Thus, the patient may be referred
o surgery without repeated FNAB. Conversely, the risk of
ancer is about 0–7% in thyroid nodules those are negative
or all these mutations [196,211]. In this lowest risk group,
ollow-up is sufficient without the necessity of surgical
ntervention. As has been recommended in the revised ATA
uideline, the use of mutational analyses in FNAB samples is
seful for pre-operative evaluation and clinical management
f thyroid nodules, especially those which are indeterminant.
In addition to somatic mutations, changes in gene expres-
ion profiles detected by microarray techniques and some
iRNA markers have been identified and may be of poten-
ial use for diagnostic purposes in thyroid cancer [26,32,178].
pregulation or aberrant expression of HMGA2, MET, TPO,
IMP1, DPP4, TFF3, SERPINA1, TIMP1, FN1, TGFA,
RABP1, FCGBP, EPS8 and PROS1 genes have been
etected in malignant thyroid tumors [215–220]. Diagnos-
ic use of expression levels and profiles of multiple genes
ave been tested and it is reported that the sensitivity and
pecificity of these techniques in differential diagnosis of
alignant and benign thyroid nodules were 92% and 84%,
espectively [221]. Mathur et al. have explored the diagnostic
tility of combined use of mutational analysis, gene expres-
ion profiling and classical cytological evaluation of FNAB
amples [222]. This study suggested that combined use of
hese molecular analyses has improved diagnostic accuracy
f FNABs. However, no reliable single marker was identi-
ed and diagnostic use of micro-array technology in routine
ractice on FNAB samples is currently not only feasible but
lso cost-effective.
There are several studies reporting overexpression of miR-
As including miR-222, miR-221, and miR-146b in PTC and
hese miRNAs may be of diagnostic potential [143–151]. In
 recent study, a panel of seven miRNAs was used in thyroid
NAB samples [223]. When presence of up-regulation of
hree or more of these miRNAs including miR-222, miR-221,
iR-146b, miR-224, miR-155, miR-187 and miR-155 was
ccepted as a predictor of thyroid cancer, diagnostic accuracy
r
o
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f FNAB was 98% [223]. This result suggests that diagnostic
se of miRNA analysis is feasible and improves diagnostic
ccuracy of thyroid FNABs in preoperative evaluation. How-
ver, their clinical use in routine practice requires additional
tudies.
.  Targeting  molecular  pathways  for  the  treatment  of
hyroid  cancer
Currently, novel therapy regimens for thyroid cancer have
een developed using therapeutic targets such as BRAF, RET,
EK and AKT, and tested at different stages of clinical trials.
he results of these clinical studies give information on thera-
eutic efficacy of these therapies and their potential use alone
r in combination with other treatment strategies for thyroid
ancer (Table 2). These novel therapeutic regimens will be
seful particularly for the treatment of MTC, non-radioiodine
vid DTC’s, and aggressive types of thyroid cancer, including
oorly differentiated and ATC’s.
.1.  Targeting  BRAF
Due to the high frequency of BRAF mutations in thyroid
ancers and its association with tumor dedifferentiation and
esistance to radioiodine therapy, several BRAF inhibitors
ave been recognized and tested as potential therapeutic
gents. Moreover, since BRAF takes place downstream of
ET and RAS in the signaling cascade, BRAF inhibitors
ere suggested to be potentially effective in tumors with
ther mutations that affect the signaling pathway upstream
f BRAF.
A promising BRAF inhibitors is BAY 43–9006, a multiki-
ase inhibitor, which effectively inhibits wild-type BRAF and
he kinase activity of mutant V600E BRAF [224]. This agent
as also been shown to have potent activity against VEGFR-
, VEGFR-3, FLT-3, c-KIT and PDGFR  kinases [225]. In a
tudy, oral administration of BAY 43-9006 resulted in a strong
ntitumor effect in xenograft models of various types of can-
er. The results demonstrated that this effect was through
nhibition of MAPK signaling and angiogenesis [225]. In
reclinical studies, BAY 43-9006 has been shown to hinder
RAF signaling and inhibit the growth of all thyroid cancer
ell lines carrying the mutant BRAF  [226]. It was also shown
o impair the growth of the ATC cell line xenografts in nude
ice [228]. Recently, the therapeutic effects of BAY 43-9006
n cells carrying the activated forms of RET and RET/PTC
ere also demonstrated [227].
BAY 43-9006, another BRAF inhibitor, has also been
ested in clinical studies for several types of cancer, includ-
ng thyroid cancer. In the trial of patients with progressive
apillary carcinoma, some patients had minimal or partial
esponse [228,229].
The efficiency of AAL-81 and LBT-613, other inhibitors
f RAF kinases, have been tested in thyroid cells in preclinical
tudies [230]. Both agents were determined to inhibit MAPK
O. Omur, Y. Baran / Critical Reviews in Oncology/Hematology 90 (2014) 233–252 243
Table 2
Completed/ongoing phase I/II trials with molecular therapy and their published response rates for thyroid cancers (NOR: no objective responses).
Agents Completed/ongoing
phase I, II, III trial
Molecular target Response rates Refs.
Everolimus Phase II completed mTOR inhibitor 5% [254]
Lenvatinib Phase II completed Tyrosine kinase inhibitor targeting VEGFR1-3,
FGFR1-4, RET, KIT and PDGFR
50% [255]
Gefitinib Phase II completed Inhibition of EGFR NOR [256]
Depsipeptide (DEP) Phase II completed Histone deacetylase inhibition NOR [257]
Vorinostat Phase II completed Histone deacetylase inhibition NOR [258]
Axitinib Phase II completed Inhibition of VEGFR 30% [259]
Sorafenib Phase II completed Inhibiting Raf kinase, VEGFR, PDGFR, and RET
tyrosine kinases
23% [260]
Suberoylanilide hydroxamic acid Phase I completed Inhibits histone deacetylase activity in
peripheral-blood mononuclear cells (PBMNCs)
30% [261]
Motesanib Phase II completed Inhibitor of VEGF R, PDGFR and KIT 14% [262]
Thalidomide Phase II completed Inhibit angiogenesis induced by bFGF or VEGF
in vivo
18% [263]
Pazopanib Phase II completed Tyrosine-kinase inhibitory 49% [264]
XL-184 Phase I completed MET, VEGFR-2 and RET kinase inhibitor 26% [265]
XL-184 Phase II completed MET, VEGFR-2 and RET kinase inhibitor 21% [265]
Imatinib Phase II completed Tyrosine-kinase inhibitor NOR [266]
Celecoxib Phase II completed Selectively COX-2 inhibiting 3% [267]
Combretastatin A4 phosphate Phase II completed Tubulin-binding vascular disrupting agent NOR [268]
Sunitinib Phase II completed Inhibitory activity against RET, VEGFR, and PDGFR 13% [269]
Selumetinib (AZD6244) Phase II completed RAF/MEK/ERK (MAPK) signaling 3% [270]
Vandetanib Phase III completed Inhibitor of RET kinase, VEGFR and EGFR signaling 37% [271]
Vandetanib Phase II completed Inhibitor of RET kinase, VEGFR and EGFR signaling 20% [272]
Lenalidomide Phase II completed Inhibit tumor necrosis factor production 22% [273]
Cabozantinib Phase III completed Tyrosine kinase inhibitor (TKI) of MET, VEGFR2,
RET, MTC
28% [274]
Thyrotropin Phase I/II completed 131I uptake and Tg release NOR [275]
Fosbretabulin Phase I completed Tubulin inhibitory NOR [276]
Romidepsin Phase I/II completed Histone deacetylase inhibition NOR [277]
Doxorubicin and interferon  Phase II completed Inhibits the enzyme topoisomerase II 6% [278]
Rosiglitazone Phase II completed PPAR 25% [279]
Cisplatin Phase II completed Microtubulin inhibitor NOR [264]
Decitabine Phase II Ongoing Inhibiting DNA methyltransferase No study results posted yet [264]
Temsirolimus + sorafenib Phase II Ongoing Inhibiting Raf kinase, VEGFR, PDGFR, RET tyrosine
kinases, mTOR
No study results posted yet [264]
Nintedanib (BIBF1120) Phase II Ongoing Inhibits receptors of VEGF, FGF and PDGF No study results posted yet [264]
Pazopanib hydrochloride Phase II Ongoing Tyrosine kinase inhibitor of VEGFR-1, VEGFR-2,
VEGFR-3, PDGFR-a/, and c-kit
No study results posted yet [264]
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Uotesanib Phase II completed Inhibits VEGF
ignaling and growth of human thyroid tumor cell lines and
at thyroid cells carrying the V600E BRAF and RET/PTC1
utations. The growth of BRAF mutant tumor xenografts in
ude mice was also shown to be suppressed [231].
Potential therapeutic targets along the MAPK pathway
re also found downstream of BRAF. A non-ATP competi-
ive MEK inhibitor has been designated as CI-1040, and it
as shown to inhibit the growth of BRAF mutant xenografts
erived from various tumor types [232]. This study has also
rogressed to clinical trials.
.2.  Targeting  RET  mutations  and  RET/PTCActivated RET kinase has been identified as a target by
everal small-molecule tyrosine kinase inhibitors in preclin-
cal and clinical studies. ZD6474 is an orally active low
M
d14% [262]
olecular weight receptor tyrosine kinase inhibitor, which
as shown to inhibit VEGFR-2 and block RET tyrosine
inase [233]. ZD6474 was demonstrated to block phosphor-
lation and signaling from RET/PTC3 in  vitro. In that way,
he growth of human papillary carcinoma cell lines harbor-
ng RET/PTC1 and RET/PTC3-transformed fibroblasts was
rrested in nude mice [234,235].
In a clinical trial with metastatic familial MTC patients,
D6474 therapy was reported to give some evidence of
esponse [232]. Currently, a multi-center phase II double
linded study is being conducted to compare the efficiency of
D6474 (ZACTIMATM, AstraZeneca Pharmaceuticals, DE,
SA) versus  placebo in patients with familial and sporadic
TC.
The antitumor activity of ZD6474 was suggested to be
ue to a combination of antiangiogenic activity mediated by
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locking VEGFR and anti-RET activity of the agent. There-
ore it is important to explore whether the presence of the
ET mutation and its type affect the extent of the therapeutic
esponse to ZD6474.
In preclinical studies, it was shown that ZD6474 can
nhibit all the mutated variants of RET except for the V804L
nd V804M mutations [235]. V804 corresponds to the gate-
eeper residues of PDGFR, c-KIT, ABL, and EGFR kinases,
nd mutations at these residues result in resistance to vari-
us inhibitors [236]. These results suggest that RET V804L
nd V804M mutations in medullary carcinomas may show
rimary resistance to ZD6474 [235].
A multikinase inhibitor SU12248 (Sunitinib) has been
emonstrated to effectively block signaling from RET/PTC
inase. Sunitinib was also tested in Phase II clinical
rial in radioiodine-refractory, unresectable DTC [237].
dditionally, in preclinical studies, the pyrazolopyrimidine
ompounds PP1 and PP2, two small-molecule tyrosine kinase
nhibitors, have been shown to effectively inhibit RET/PTC
ignaling in  vivo  and abolish its oncogenic effects in experi-
ental animals [238,239].
.3.  Targeting  RAS
Point mutations of RAS  occur in both benign and malig-
ant thyroid tumors. In PTCs, RAS mutations are found at
elatively low frequencies, in approximately 10% of tumors.
n follicular thyroid carcinomas, 40–50% of tumors carry
AS mutations [87,91,96], which may correlate with poor
rognosis and tumor dedifferentiation [97,240]. RAS  muta-
ions may influence tumor dedifferentiation, as they are found
ith high frequency in ATCs. In  vitro  studies have provided
vidence that the mutant RAS affects chromosomal stability
241,242]. Active RAS may induce thyroid tumorigenesis
hrough the classic MAP kinase pathway or through inter-
ction with the PI3K/Akt pathway. RAS  mutations, however,
re not specific for thyroid tumors, they can also occur in
enign follicular adenomas.
.4.  Targeting  PI3K
Previous studies have shown that activation of PI3K
ignaling is a common feature of many cancers including
hyroid cancer [243]. Particularly, FTCs have been identi-
ed to have greater levels of Akt activation as compared to
TCs [74,75]. Genetic changes that activate the MAPK and
I3K/Akt pathways were shown to be present in most (81%)
TC cases. Since both the MAP kinase and PI3K pathways
re involved in the pathogenesis of ATC, targeting multiple
ignaling pathways may be a valuable therapeutic approach
or thyroid cancer. Downstream signaling relay molecules
uch as BRAF, AKT, MEK and mTOR are examples of
herapeutic targets that are being actively tested for the treat-
ent of thyroid cancer [27]. In a recent study, the activity
f the PI3K inhibitor GDC-0941 was assessed on hypoxia-
nducible-factor-1 (HIF-1), a transcription factor regulated
i
c
m
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y PI3K, for its metastatic behavior of thyroid cancer cells
oth in  vitro  and in  vivo  [164]. GDC-0941 has been shown to
nhibit HIF-1  and HIF-2  expression, and HIF activity in
hyroid carcinoma cells. In  vivo, GDC-0941 has been demon-
trated to decrease HIF-1  expression in FTC xenografts, and
educe FTC tumor growth and metastatic lung colonization.
In a transgenic mouse model where a mutant thyroid
ormone receptor   gene (TRPV) was knocked-in, the acti-
ation of the PI3K/Akt pathway was determined following
he interaction of TRPV with the p85  regulatory subunit of
I3K, and spontaneous development of FTCs was observed
81,82]. Several human tumor studies proposed that acti-
ation and nuclear localization of Akt1 is involved in the
nvasiveness and metastatic behavior of FTC triggered by
he PI3K/Akt pathway [75]. This result was supported by
he detection of Akt1 mutations in metastatic thyroid can-
ers [84]. On the other hand, excision of Akt1 was shown
o delay and prevent tumor development, angiogenesis, and
ovement of FTC to distant sites in TRPV mice [85]. In
nother study it was shown that treatment with LY294002,
 PI3K inhibitor, prevents tumor development [244]. Several
rugs have been developed to target the PI3K/Akt pathway,
nd their efficiency for the treatment of cancer is currently
ssessed in various clinical studies [245].
.5.  Targeting  PPAR
To date, there is no definite evidence that PAX8/PPR
earrangement could be a sign of outcome in FTCs. There-
ore, its use as a novel therapeutic target for FTC has been
ncertain. However, a number of approved, well-tolerated,
rally administered regulators of the PPAR  pathway are
vailable, and are used in the treatment of type 2 diabetes.
urrently, some clinical trials are ongoing with PPAR
gonists, alone or in combination with other conventional
hemotherapeutic agents [246].
.6.  Targeting  NF-κB
The NF-B pathway has a significant role in the regula-
ion of inflammatory responses that are linked to oncogenesis
247], and increased NF-B activation has been well docu-
ented in thyroid cancer cell lines [134–136]. In one study,
t was shown that concurrent suppression of the NF-B and
EK–ERK pathways through application of NF-B and
EK inhibitors repressed the proliferation of thyroid cancer
ells carrying a BRAF-V600E mutation [248].
.7.  Targeting  epigenetic  mechanisms
Epigenetic alterations in thyroid tumors include changes
hat occur in DNA methylation patterns in the CpG
slands of promoters of genes important in normal thyro-
yte function and increased promoter methylation by DNA
ethyltransferases (DNMTs) causing gene silencing and
edifferentiation [249,250]. Studies on how posttranslational
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odification of histones may influence cancer have recently
ained significance. The nucleosome consists of 147 bp of
NA wrapped around an octamer of four core histone
roteins (H2A, H2B, H3, and H4) [251]. Methylation, acety-
ation, phosphorylation, and ubiquitination are included in
istone modifications that synergistically act with DNA pro-
oter methylation to regulate gene silencing [252]. It is
elieved that epigenetic drug targets will play a more sig-
ificant role in cancer treatment in the near future.
DNMT inhibitors such as 5′-azadeoxycytidine have been
ested as “redifferentiation” agents, which allow tumors to
egain their sensitivity to conventional radioactive iodine
herapy [253]. A summary of ongoing or completed trials
f treatment of thyroid cancers with molecular therapy is
resented in Table 2.
.  Current  challenges  and  future  venues  for  research
n molecular  therapy  of  thyroid  cancers
In the near future, increased access to array-type and next
eneration sequencing technologies will provide significant
rogress in our understanding of the molecular biology of
hyroid cancers. Novel information including new mutations,
enes and/or signaling pathways that are involved in initiation
r progression of thyroid cancers may be an important avenue
or diagnosis and prognosis of thyroid cancers. Therefore,
etermination of nucleotide sequences of genes, rearrange-
ents and expression levels of the genes should become
ommon diagnostic tools.
Targeting certain molecules involved in initiation and pro-
ression of thyroid cancers will also be an important research
rea. However, it is vital to determine whether the genetic
ifferences observed in thyroid cancers correlate with the
herapeutic response to specific inhibitors. Acquired and
ntrinsic drug resistance mechanisms and reversal of drug
esistance are also important considerations for a complete
ure.
On the other hand, environmental factors and sporadic
onditions that induce thyroid cancer need to be addressed
n order to clarify the increasing rates of thyroid cancers in
arious parts of the world in the last three decades. Overcom-
ng these challenges will provide better prevention, diagnosis
nd therapy of thyroid cancers.
.  Conclusion  and  future  directions
The contribution of multiple signaling pathways in the
evelopment of aggressive thyroid cancer suggests that it
ay be necessary to target them simultaneously for success-
ul treatment. Indeed, clinical trials undertaken with single
inase inhibitors in thyroid cancer have generally shown only
artial responses. Recently, various preclinical studies test-
ng the combination of MEK or BRAF–V600E inhibitors
ith AKT, PI3K, or mTOR inhibitors demonstrated that they elogy/Hematology 90 (2014) 233–252 245
nhibit proliferation and induce apoptosis of thyroid cancer
ells synergistically [280–282].
Novel and promising treatment strategies for thyroid
ancers are based on molecular targeting [283]. New small-
olecule protein-kinase inhibitors including axitinib [259],
orafenib [260,284,285], motesanib [262] and pazopanib
264] have shown promise in clinical trials on thyroid cancer.
LX4032 (also known as vemurafenib), a BRAF-V600E-
pecific inhibitor, has been recently approved by the FDA
or the treatment of BRAFV600E-positive melanoma [286].
Targeting multiple signaling pathways in order to restore
adioiodine avidity can be considered as another promis-
ng area of translational research on thyroid cancer. It was
ecently demonstrated that simultaneous inhibition of the
APK, PI3K–AKT and histone deacetylase pathways could
timulate the expression of thyroid iodide-handling genes in
hyroid cancer cells as compared to inhibition of one pathway
lone [287].
In conclusion, remarkable progress has been made in
nderstanding the molecular biology of thyroid cancer in
ecent years. This understanding of the molecular patho-
enesis of thyroid tumorigenesis has now opened great
pportunities for the development of novel molecular-based
pproaches for the effective management of the diagnostic
nd therapeutic obstacles of thyroid cancer.
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